Growth in line, margins compressed; capex upside ahead but near-term unproven
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Missed 15% revenue CAGR guidance (delivered 11.7%). Multiple margin expansion claims hedged with 'temporary' language. Margins still under pressure.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered 11.7% revenue growth and 36.7% PAT growth, but this misses the prior 15% minimum CAGR guidance. Hospital EBITDA margin compressed 320 bps despite occupancy gains, blamed on doctor ramp timing. Management is confident margins will recover and capex investments will drive ROCE expansion to 11-13%, but execution remains unproven. Key risk: margin recovery relies on new doctor productivity proving out in Q2-Q3.
₹338.6 Cr
Revenue · +11.6% YoY₹10.5 Cr
Reported PAT · +36.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Hospital EBITDA margin to improve 'from here on'
MISSMargin compressed 320 bps YoY to 18.4%; management attributes to new doctor deployment, temporary
Confident to sustain healthy growth and profitability
OVERSTATEDRevenue growth 11.7% YoY vs prior 15% minimum CAGR guidance; below target
Gurgaon achieved EBITDA breakeven and 'sustainable growing EBITDA'
METConfirmed ₹2 Cr revenue at Gurgaon with EBITDA positive for first time; still 24% occupancy (targeting 30%)
MedTech on path to double-digit EBITDA margins
OVERSTATEDConsolidated EBITDA ₹1.7 million on ₹47 Cr (0.036% margin); US operation still marginally negative; timeline vague
Occupancy improved and beds growth of 9.8%
METBeds 701 vs 639 YoY (+9.8% confirmed); standalone occupancy 51% (up from implicit ~47% prior); supported
Earnings quality
What changed since the last call
Hospital margins deteriorated
DowngradeStandalone EBITDA margin fell from 21.6% (Q1 FY26) to 18.4% (Q1 FY27), -320 bps; management cited temporary doctor ramp impact but no guarantee on recovery speed
Gurgaon posted EBITDA breakeven
UpgradeGurgaon unit achieved EBITDA positive for first time since acquisition; management positioned as sustainable inflection, though occupancy still only 24%
MedTech barely profitable
DowngradeConsolidated MedTech EBITDA ₹1.7 million on ₹47 Cr revenue (vs 53% YoY growth); US operation marginally negative; forex headwinds cited but underlying profitability remains weak
ICRA rating downgraded
DowngradeLong-term rating moved A+ to A in late July 2026; however outlook improved from negative to stable; ₹129 Cr Kotak facility is debt refinance not new issuance
Revenue growth miss prior guidance
DowngradeQ1 revenue growth 11.7% YoY vs prior stated 'minimum 15% CAGR' expectation; confirms near-term growth momentum slower than expected
The Q&A
Analysts pressed on margin compression (Kashish Thakur) and MedTech profitability weakness (Kashish Thakur, Rajakumar). Management defended margins as temporary and cited specific cost initiatives (₹3 Cr/month reduction already, ₹3 more by Q4). Analyst acceptance was moderate; several commitments remained unquantified (MedTech double-digit margin timing, Mumbai capex). Mumbai expansion question drew non-committal response (discussions underway). Overall: professional defense but lacked firm commitments.
Hospital margins sustainability — Rajakumar, RK Invest
AnsweredConfident margins improve from Q2 onwards. Reasons: bunkers deployed last year now active; TPA renewals underway (5-7% upside); Gurgaon EBITDA positive; Krishna/Mohali/Naroda showing 30% YoY growth. Surat/Indore underperforming but doctor recruitment ongoing.
MedTech bottom-line deterioration — Rajakumar, RK Invest
PartialEBITDA posting positive numbers. Earlier years investing caused interest expense, now debt stable. Depreciation on capex is the delta. Do not expect bottom line to worsen; 100-200 bps quarterly gross margin improvement expected.
MedTech QoQ loss increase — Rajakumar, RK Invest
AnsweredOne-off: prior quarter had forex gain which reversed in current quarter. Once stabilizes, one-off gone and improving trend visible.
MedTech profitability path — Kashish Thakur, Elara Securities
PartialForex headwinds material. India volume growth >100%, US flat. Cost initiatives in Q1 reduce inflow ₹3 Cr/month; another ₹3 Cr by Q4 FY27. FDA changes take 6-9 months or one year; half progress done, half expected next 6 months. Will achieve double-digit margins once implemented.
Hospital occupancy vs margin gap — Kashish Thakur, Elara Securities
AnsweredOccupancy up 600 bps. Top line increased, Krishna/Naroda 30% growth. Margin pressure temporary due to new doctor/specialty deployment; takes ~1 quarter for profitability reflection. TPA renewals and bunker revenue flow into Q2+. Confident EBITDA margin upward to 20% FY27 basis.
Shalby International turnaround — Kashish Thakur, Elara Securities
AnsweredTargeting 30% occupancy from Q3/Q4 onwards. Likely PBT positive in Q3/Q4 end or 6-9 months timeframe. Specialties already deployed. Not far from EBITDA positive; posted 7% EBITDA margin this quarter.
Tax rate FY27 guidance — Kashish Thakur, Elara Securities
AnsweredHospital transitioned to new tax scheme: 26% rate vs prior 35%. ETR at group level down to 47% from 66% in Q1 FY26. Gurgaon carries forward losses; no tax expense for next 2-3 years once PBT positive.
ROCE expansion — Kashish Thakur, Elara Securities
PartialStandalone 9.5%, group 7%. CAPEX deployment heavy in recent years (₹160 Cr including bunker, robotics, MedTech). Minimal capex planned FY27+. Expect ROCE fall within industry standard 11-13% in 1-2 years via EBITDA improvement.
Mumbai expansion status — Kashish Thakur, Elara Securities
DodgedDiscussions underway with trustees. Once alignment achieved, will go to trust office for approval. Will inform stakeholders on developments.
ICRA downgrade drivers — Tripti Shukla, Kedia Securities
AnsweredRating downgrade procedural; their parameters. Outlook improved negative to stable; can be re-evaluated upward in coming quarters. New ₹129 Cr facility is replacement at 30 bps lower cost, not new debt. No net debt increase; stable or reducing trend expected.
Government payer mix shift — Tripti Shukla, Kedia Securities
AnsweredGovernment increase follows rate renewal and review. Krishna unit secured super-specialty rate. Bunker treatment now in govt scheme. Gurgaon CGHS rate better. Deployed automated tools, bill submission processes, active follow-up with govt officials to secure cash cycle.
ROCE vs Mumbai capex trade-off — Tripti Shukla, Kedia Securities
DodgedMumbai greenfield project; different benchmark when finalized. Will not need further debt investment in hospitals or MedTech post-Gurgaon. Will assess at that time via debt or internal accruals.
Guidance
No explicit FY27 consolidated revenue guidance given
LowPrior call stated 'minimum 15% CAGR' but Q1 delivered only 11.7% YoY; no reset guidance provided
Hospital EBITDA margin upward to 20% for FY27
MediumQ1 at 18.4%; management cites bunker/TPA uplift in Q2+; new doctor productivity assumed to flow through but unproven timing
MedTech double-digit EBITDA margins from here on
LowTimeline vague; depends on FDA changes (6-9 months), cost initiatives (₹6 Cr/month reduction), currency stabilization; currently 0.036% consolidated margin
Minimal CAPEX expected FY27 (major deployment complete)
High₹160 Cr deployed in recent years on bunker, robotics, MedTech; no large capex planned beyond potential Mumbai greenfield (timing unclear)
Risks the call surfaced
Margin pressure, hospital segment
HighHospital EBITDA margin fell 320 bps YoY to 18.4% despite occupancy gains. Management attributes to doctor ramp timing but no recovery roadmap with numbers. If new doctors fail to generate expected productivity, margins could stay compressed.
MedTech profitability and scale
HighConsolidated MedTech EBITDA ₹1.7 million on ₹47 Cr revenue (0.036% margin). US operation still marginally negative. Management claims double-digit EBITDA margins achievable but timeline vague (6-9 months for regulatory changes). Forex headwinds cited but reflect underlying US unit weakness.
Prior guidance miss
MediumPrior calls stated 'minimum 15% CAGR' expectation. Q1 delivered 11.7% YoY revenue growth, below target. No updated guidance provided. Signals potential miss on full-year targets if trajectory doesn't accelerate.
ROCE expansion execution
MediumConsolidated ROCE 7%, standalone 9.5%. Management targets 11-13% in 1-2 years. Prior capex ₹160 Cr deployed on bunker, robotics, MedTech. If EBITDA growth doesn't materialize or new investments (Gurgaon, Mumbai) underperform, ROCE targets could slip.
Shalby International Gurgaon execution
MediumGurgaon achieved EBITDA breakeven at only 24% occupancy. Management targets 30% occupancy from Q3/Q4 and PBT positive in 6-9 months. Risk: occupancy growth may stall if patient acquisition slows; international revenue (42% of operating) could be volatile.
ICRA credit rating downgrade
LowLong-term rating downgraded A+ to A in July 2026. While outlook improved negative to stable, downgrade signals credit pressure. Could affect future refinancing costs and borrowing terms.
Government payer mix concentration
LowGovernment payer mix increased from 24% to 32% YoY. While management secured rate improvements (super-specialty in Krishna, CGHS in Gurgaon), extended receivable cycles and policy changes pose risk. ARPOB compressed YoY to ₹44,711.
Management
Score 6/10. Professional and detailed on metrics but vague on timelines for margin recovery and MedTech profitability. Acknowledged headwinds (doctor ramp, forex) but defensive on margin compression. Forward claims (20% margin, double-digit MedTech EBITDA) unquantified on timing. Mixed. Hospital bed additions and occupancy gains on track (+600 bps). Gurgaon achieved EBITDA breakeven (positive). But prior 15% revenue CAGR guidance missed (11.7% delivered). MedTech margin expansion significantly delayed and unproven.
1 · Q2 FY27
New doctor profitability contribution and bunker/TPA revenue uplift should flow through hospital margins
2 · Q4 FY27
US MedTech regulatory changes (FDA-related) implemented; second tranche of ₹3 Cr/month cost savings activated
3 · Q3/Q4 FY27
Gurgaon unit targeting 30% occupancy and PBT breakeven (from 24% occupancy and EBITDA breakeven currently)
Key risk: margin recovery relies on new doctor productivity proving out in Q2-Q3.
Shalby Q1FY27: consolidated PAT +37% YoY on lower tax, PBT falls 13%, margins compress
PAT +36.71% YoY · revenue +11.74% · margins compressing
₹331.22 Cr
+11.74% YoY
₹10.5 Cr
+36.71% YoY
3.1%
+0.6pp YoY
₹0.98
Shalby's consolidated revenue rose 11.7% YoY to ₹331.22 Cr (+15.2% QoQ) for Q1 FY27, but consolidated profit before tax fell 13.1% YoY to ₹19.70 Cr as core margins compressed — operating margin (OPM) slipped to 12.56% from 14.01% a year ago. Reported PAT (period total, before non-controlling interest) grew 36.7% YoY to ₹10.50 Cr, but this is almost entirely a function of a lower effective tax rate this quarter (46.7% vs 66.1% in Q1 FY26) rather than operating improvement — PBT itself declined. No street/consensus estimates for this quarter turned up in available coverage, so vsStreet is unknown. On a QoQ basis PAT fell 43.1% from ₹18.45 Cr in Q4 FY26, though that base included unusually large tax credits specific to the year-end quarter, making the sequential comparison less meaningful than the YoY read.
Q1 FY-2027 vs prior quarters
The margin compression traces to the Manufacturing & Trading of Implants (MedTech) segment: its revenue jumped 51.1% YoY to ₹42.41 Cr but its segment loss widened 15.8% YoY to ₹11.48 Cr, eating into the ₹31.18 Cr PBT the Healthcare Services segment generated (down 4.3% YoY from ₹32.57 Cr). Healthcare Services segment revenue grew just 7.6% YoY to ₹288.81 Cr, tracking below management's guided minimum 15% CAGR floor for the hospital and pharma business laid out on the Q4 FY26 call, and margins have not shown the 'continued improvement' management said it expected for FY27 — on both counts this quarter runs behind prior guidance, so vsGuidance is 'missed'. Standalone tells a similar but sharper story: standalone PBT fell 15.5% YoY and standalone PAT fell 2.5% YoY to ₹25.07 Cr even as standalone revenue grew 7.3% YoY — the wide gap between standalone (-2.5%) and consolidated (+36.7%) PAT growth is a basis divergence worth flagging, since the consolidated figure benefits far more from the lower tax rate.
The stock went into the print at ₹157.28, down 5.1% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management is confident in sustained healthy growth and profitability for FY27 and beyond. While specific numbers are withheld, they anticipate significant upside driven by recent capex investments, improved operational efficiencies, and expanded market penetration for both the hospital and MedTech segments. They expec
— This quarter: missed
The Board, at the same meeting, appointed Shanay Vikram Shah as Whole-Time Director for five years; no separate management press release accompanied this filing. The quarter's other developments include a ₹129.70 Cr working capital facility secured from Kotak Mahindra Bank (Jul 30) and disposal of a pending arbitration matter (Jun 27) — neither materially explains the P&L movement. Going into Q2 FY27, the print sets up two open questions: whether MedTech segment losses (₹11.48 Cr this quarter) narrow as it scales toward management's INR600-650 Cr by 2030 revenue target, and whether Healthcare Services growth re-accelerates toward the guided 15% floor, since the current 7.6% YoY pace and 12.56% OPM would need to improve materially to match the confident tone management struck on the Q4 FY26 call.
W1
Whether MedTech/Implants segment losses (₹11.48 Cr this quarter) narrow as revenue scales toward management's INR600-650 Cr by 2030 target
W2
Whether Healthcare Services segment revenue growth re-accelerates toward the guided minimum 15% CAGR (ran at 7.6% YoY this quarter)
W3
Whether OPM recovers from 12.56% back toward the 14%+ levels implied by management's guidance for continued EBITDA margin improvement in FY27
Statement is in ₹ Million, converted to Cr. Consolidated PAT of ₹10.496 Cr is the 'profit for the period' before NCI split (matches context basis); profit attributable to shareholders alone is ₹10.845 Cr (NCI -₹0.349 Cr). No exceptional items in current or year-ago quarter for either statement, so no adjusted-growth calc needed. Q4 FY26 (QoQ base) carried unusual tax credits/MAT write-off, making QoQ comparison less meaningful than YoY.